Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cns Pharmaceuticals Inc (NQ: CNSP )

1.930 -0.140 (-6.77%)
Streaming Delayed Price Updated: 1:50 PM EST, Dec 11, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cns Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 8 9 Next >
Plants Could Unlock Future Cancer Therapies
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Focused on Advancing Research on Treatments for GBM, Other Cancers
Via Investor Brand Network
JTC Team Announces Continuation of its Virtual Investor Spotlight Series with NASDAQ: AEZS, NASDAQ: CNSP, and NASDAQ: AREC
- Live video webcast events on Thursday, April 14 at 10 AM ET, 11:30 AM ET and 1 PM ET - FRENCHTOWN, NJ / ACCESSWIRE / April 13, 2022 / JTC Team ("JTC"), a fully integrated corporate communications and... 
From JTC Team, LLC
Via AccessWire
European Regulatory Approvals Help CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advance ‘Potentially Pivotal’ Study of Novel Brain Cancer Drug
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) to Participate in Upcoming Virtual Investor Event
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate in Upcoming Virtual Investor Event
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Leading the Charge toward Advancing Research on Treatments for Primary and Metastatic Central Nervous System Cancers
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Approval from France EC and ANSM Competent Authority for Potentially Pivotal Study of Berubicin
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Receives Key Approval for Pivotal Study of Berubicin
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Receives Key Approval for Pivotal Study of Berubicin
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) CEO Shares Company Highlights at Virtual Growth Conference
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO John Climaco Shares Company Highlights, Goals at 2022 Virtual Growth Conference Presented by Maxim Group LLC
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) to Participate at 2022 Virtual Growth Conference
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate at the 2022 Virtual Growth Conference
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) CEO Discusses Milestone in Advancing Berubicin
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Significant Milestone in Advancing Berubicin
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Reiterates Progress for Lead Product Candidate
Via Investor Brand Network
Exposures Product Safety
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reiterates Progress for Lead Product Candidate, Addresses Recent Share Price Activity in Video to Shareholders
Via Investor Brand Network
Exposures Product Safety
CNS Pharmaceuticals (NASDAQ: CNSP) Gives Corporate Presentation, Q&A Session
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Gives Corporate Presentation, Q&A Session at Virtual Investor 2022 Top Picks Conference
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Announces 2021 Financial Results, Corporate Update
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 2021 Financial Results, Corporate Update
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Laying Foundation for Potentially Pivotal Global Trial
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Laying Robust Foundation for Potentially Pivotal Global Trial
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Marks Milestone in Pursuit of Berubicin Approval for GBM
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Marks Significant Milestone in Pursuit of Berubicin Approval for Global GBM Treatment, Raises $11.5 Million from Private Placement
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) to Present at Virtual Investor 2022 Top Picks Conference
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Virtual Investor 2022 Top Picks Conference
Via Investor Brand Network
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ /... 
From JTC Team, LLC
Via AccessWire
CNS Pharmaceuticals (NASDAQ: CNSP) Closes on $11.5M Private Placement
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.